The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Regulatory CD56 bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
Abstract
Administration of daclizumab, a humanized mAb directed against the IL-2Rα chain, strongly reduces brain inflammation in multiple sclerosis patients. Here we show that daclizumab treatment leads to only a mild functional blockade of CD4 + T cells, the major candidate in multiple sclerosis pathogenesis. Instead, daclizumab therapy was associated with a gradual decline in circulating CD4 + and CD8 + T cells and significant expansion of CD56 bright natural killer (NK) cells in vivo , and this effect correlated highly with the treatment response. In vitro studies showed that NK cells inhibited T cell survival in activated peripheral blood mononuclear cell cultures by a contact-dependent mechanism. Positive correlations between expansion of CD56 bright NK cells and contraction of CD4 + and CD8 + T cell numbers in individual patients in vivo provides supporting evidence for NK cell-mediated negative immunoregulation of activated T cells during daclizumab therapy. Our data support the existence of an immunoregulatory pathway wherein activated CD56 bright NK cells inhibit T cell survival. This immunoregulation has potential importance for the treatment of autoimmune diseases and transplant rejection and toward modification of tumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
Viglietta, V., Baecher-Allan, C., Weiner, H. L., & Hafler, D. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031579 · Cited by 1,856
Determination of lymphocyte division by flow cytometry
Lyons, A. B., & Parish, C. R. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90236-4 · Cited by 1,657
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
Setoguchi, R., Hori, S., Takahashi, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041982 · Cited by 1,235
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Fehniger, T. A., Cooper, M. A., Nuovo, G. J., Cella, M., Facchetti, F., Colonna, M., & Caligiuri, M. A. (2003) · Blood · doi:10.1182/blood-2002-09-2876 · Cited by 857
A humanized antibody that binds to the interleukin 2 receptor.
Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10029 · Cited by 627
Self-citationT cell fitness determined by signal strength
Gett, A. V., Sallusto, F., Lanzavecchia, A., & Geginat, J. (2003) · Nature Immunology · doi:10.1038/ni908 · Cited by 473
Immune Responses in Interleukin-2-Deficient Mice
Kündig, T. M., Schorle, H., Bachmann, M. F., Hengartner, H., Zinkernagel, R. M., & Horak, I. (1993) · Science · doi:10.1126/science.8235625 · Cited by 462
Cited by
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
Self-citationMalek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Multiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985
“However, the additional regulatory cell type that has been noted in daclizumab-treated patients with multiple sclerosis belongs to the natural killer lineage and is characterized as 'CD56 bright”
BackgroundSelf-citationCD56bright natural killer (NK) cells: an important NK cell subset
Poli, A., Michel, T., Thérésine, M., Andrès, E., Hentges, F., & Zimmer, J. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.03027.x · Cited by 977
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
Ramagopalan, S. V., Dobson, R., Meier, U. C., & Giovannoni, G. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70094-6 · Cited by 548
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
Organ-specific features of natural killer cells
Shi, F.-D., Ljunggren, H.-G., La Cava, A., & Van Kaer, L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3065 · Cited by 414
Recent Advances in Marine Algae Polysaccharides: Isolation, Structure, and Activities
Xu, S.-Y., Huang, X., & Cheong, K.-L. (2017) · Marine Drugs · doi:10.3390/md15120388 · Cited by 414
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Engineering IL-2 for immunotherapy of autoimmunity and cancer
Hernandez, R., Põder, J., LaPorte, K. M., & Malek, T. R. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00680-w · Cited by 355
Multiple sclerosis: Pathology, diagnosis and treatments
Huang, W.-J., Chen, W.-W., & Zhang, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4410 · Cited by 351
Rech, A. J., Mick, R., Martin, S., Recio, A., Aqui, N. A., Powell, D. J., Colligon, T. A., Trosko, J. A., Leinbach, L. I., Pletcher, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003330 · Cited by 337
The Immune Response in Multiple Sclerosis
Rodríguez Murúa, S., Farez, M. F., & Quintana, F. J. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052920-040318 · Cited by 335
Role of the innate immune system in the pathogenesis of multiple sclerosis
Gandhi, R., Laroni, A., & Weiner, H. L. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.10.015 · Cited by 331
Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 314
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70033-8 · Cited by 301
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
Durrenberger, P. F., Ettorre, A., Kamel, F., Webb, L. V., Sim, M., Nicholas, R. S., Malik, O., Reynolds, R., Boyton, R. J., & Altmann, D. M. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-1 · Cited by 287
Gold, R., Giovannoni, G., Selmaj, K., Havrdova, E., Montalban, X., Radue, E.-W., Stefoski, D., Robinson, R., Riester, K., Rana, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62190-4 · Cited by 287
Wuest, S. C., Edwan, J. H., Martin, J. F., Han, S., Perry, J. S. A., Cartagena, C. M., Matsuura, E., Maric, D., Waldmann, T. A., & Bielekova, B. (2011) · Nature Medicine · doi:10.1038/nm.2365 · Cited by 284
Self-citationThe Role of Natural Killer Cells in Autoimmune Diseases
Kucuksezer, U. C., Aktas Cetin, E., Esen, F., Tahrali, I., Akdeniz, N., Gelmez, M. Y., & Deniz, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622306 · Cited by 284
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
Khatri, B. O., Man, S., Giovannoni, G., Koo, A. P., Lee, J.-C., Tucky, B., Lynn, F., Jurgensen, S., Woodworth, J., Goelz, S., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000341766.59028.9d · Cited by 282
The genetics of multiple sclerosis: an up‐to‐date review
Gourraud, P., Harbo, H. F., Hauser, S. L., & Baranzini, S. E. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01134.x · Cited by 282
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Kappos, L., Wiendl, H., Selmaj, K., Arnold, D. L., Havrdova, E., Boyko, A., Kaufman, M., Rose, J., Greenberg, S., Sweetser, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501481 · Cited by 265
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE
Van Kaer, L., Postoak, J. L., Wang, C., Yang, G., & Wu, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0221-5 · Cited by 148
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis
Laroni, A., Armentani, E., Kerlero de Rosbo, N., Ivaldi, F., Marcenaro, E., Sivori, S., Gandhi, R., Weiner, H. L., Moretta, A., Mancardi, G. L., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.04.003 · Cited by 112
The Central Nervous System Contains ILC1s That Differ From NK Cells in the Response to Inflammation
Romero-Suárez, S., Del Rio Serrato, A., Bueno, R. J., Brunotte-Strecker, D., Stehle, C., Figueiredo, C. A., Hertwig, L., Dunay, I. R., Romagnani, C., & Infante-Duarte, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02337 · Cited by 51
Chen, J., Zhang, M., Ju, W., & Waldmann, T. A. (2009) · Blood · doi:10.1182/blood-2008-04-149658 · Cited by 49
Self-citationThe efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Metadata
- Authors
- Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T. A., McFarland, H., Henkart, P. A., & Martin, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-04-11
- Volume
- 103
- Issue
- 15
- Pages
- 5941-5946
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2113485611
- Cited by
- 597
- References
- 28
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.